2025, Globus and Fourth Quarter
Digest more
Globus Medical cites successful integration of NuVasive and Nervo and strong domestic spine sales growth as drivers in strong Q4 results.
22h
Globus Medical raises 2026 EPS guidance to $4.40-$4.50 with margin gains following record Q4 results
Q4 2025 earnings call recap: revenue/EPS beats, margin expansion, Nevro integration, and raised 2026 guidance—read key ...
StockStory.org on MSN
Globus Medical (NYSE:GMED) delivers strong Q4 CY2025 numbers
Medical device company Globus Medical (NYSE:GMED) reported in Q4 CY2025, with sales up 25.7% year on year to $826.4 million.
Globus Medical (GMED) delivered earnings and revenue surprises of +20.76% and +4.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical saw nearly $3 billion in full-year net sales, according to financial results posted Feb. 24. Five things to know: 1. Net sales in 2025 were $2.93 billion, an increase of 16.7% year over ...
Globus Medical Inc. (NYSE:GMED) is one of the best medical technology stocks to invest in. On January 30, Needham upgraded ...
Globus Medical, a firm on the Top 100 Medical Device Companies List, had what some analysts are calling a disappointing quarter. The Audubon, PA-based company came up short in the revenue and ...
Zacks.com on MSN
GMED or MASI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Masimo (MASI). But which of these two stocks is more attractive to value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results